A Feasibility Study for Cryopreserving Peripheral Blood Stem Cell Collects at High Cell Concentration.
10.17945/kjbt.2015.26.1.26
- Author:
Jong Eun PARK
1
;
Hae Kyoung CHOUNG
;
Hye Kyung PARK
;
Seung Tae LEE
;
Seok Jin KIM
;
Joon Ho JANG
;
Ki Hyun KIM
;
Won Suk KIM
;
Chul Won CHUNG
;
Eun Suk KANG
;
Dae Won KIM
Author Information
1. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. eskang@skku.edu
- Publication Type:Original Article
- Keywords:
CD34 antigen;
Cryopreservation;
Peripheral blood stem cell transplantation
- MeSH:
Antigens, CD34;
Cell Count;
Cell Survival;
Cryopreservation;
Dimethyl Sulfoxide;
Feasibility Studies*;
Granulocyte-Macrophage Progenitor Cells;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma;
Multiple Myeloma;
Peripheral Blood Stem Cell Transplantation;
Stem Cells*;
Transplants
- From:Korean Journal of Blood Transfusion
2015;26(1):26-37
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: For autologous hematopoietic stem cell transplantation (HSCT), the volume of infused and DMSO contained in graft are the major causes of complications related to infusion. In this study, we evaluated feasibility of cryopreserving peripheral blood stem cell collects (PBSCC) at high cell concentration. METHODS: PBSCC from 40 patients with multiple myeloma or lymphoma were split and cryopreserved at two different concentrations of TNCs; one for standard concentration (SC) (2x108 cells/mL) and the other for high concentration (HC) (3x108 cells/mL). The viability of total nucleated cells and CD34+ cell count were examined before cryopreservation and after thawing. CFU-GM was examined with thawed products. Data were analyzed as two groups between good mobilizer (GM) and poor mobilizer (PM). RESULTS: There were no differences in TNC viability between SC and HC of all patients (P=0.0656) and PM (P=0.9658), however HC of GM showed significantly lower viability than SC (P=0.0314). CD34+ cell viability did not differ between SC and HC. CD34+ cell recovery was decreased in HC of all patients (P=0.459) and GM (P=0.0164), but no differences between SC and HC in PM (P=0.9658). CFU-GM clonogenic efficiency between SC and HC was not different in all patients (P=0.0635) and PM (P=0.8984), but was decreased in HC of GM (P=0.0427). CONCLUSION: Cryopreservation of PBSCC at 3x108 cells/mL seems to have minimal adverse effect on the quality of PBSC after thawing, particularly in PM. This approach may help to reduce infusion related complications while decreasing the cost of processing and storage of PBSCC.
